Core Viewpoint - EUDA Health Holdings Limited has secured exclusive worldwide distribution rights for a next-generation immune health supplement, enhancing its wellness product portfolio and positioning itself in the molecular precision wellness market [1][7]. Group 1: Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider based in Singapore, focusing on markets in Singapore, Malaysia, and China [1][8]. - The company aims to become a market leader in non-invasive and preventive healthcare, targeting the fast-growing longevity sector to address the healthcare needs of over 1.8 billion people in the region [8][10]. Group 2: Product Details - The newly acquired supplement, branded as Euda Helixé, is designed to modulate gene expression, enhancing metabolism, boosting vitality, and supporting longevity through advanced epigenetic technology [2][3]. - The supplement combines premium-grade ingredients and utilizes a capsule delivery system that ensures active ingredients survive stomach acid for optimal absorption [4][9]. Group 3: Market Strategy - EUDA plans to initially market and sell the supplement in Singapore, Malaysia, and China, with future expansion into other markets [2]. - The company anticipates generating sales of approximately 500,000 bottles over the next 12 months, leveraging its strong regional ecosystem and distribution capabilities [7]. Group 4: Scientific Background - The supplement is developed by Chemokine Pte. Ltd., founded by Professor Kah Meng Lim, a respected molecular medicine researcher with a Ph.D. from the National University of Singapore [6]. - The formulation builds on prior scientific advancements and proven platforms to deliver molecular-level wellness support [4].